Mirum Pharmaceuticals, Inc.
MIRM
$102.19
-$9.21-8.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.35% | 11.97% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.35% | 11.97% | |||
| Cost of Revenue | 1.91% | 10.68% | |||
| Gross Profit | 8.63% | 12.28% | |||
| SG&A Expenses | 29.95% | 19.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 45.31% | 17.71% | |||
| Operating Income | -1,283.03% | -275.45% | |||
| Income Before Tax | -15,811.34% | -287.78% | |||
| Income Tax Expenses | -38.07% | 392.75% | |||
| Earnings from Continuing Operations | -13,689.79% | -297.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13,689.79% | -297.25% | |||
| EBIT | -1,283.03% | -275.45% | |||
| EBITDA | -3,835.17% | -82.61% | |||
| EPS Basic | -11,667.22% | -298.78% | |||
| Normalized Basic EPS | -1,006.31% | -289.57% | |||
| EPS Diluted | -10,806.90% | -346.20% | |||
| Normalized Diluted EPS | -1,006.31% | -313.10% | |||
| Average Basic Shares Outstanding | 17.24% | -0.87% | |||
| Average Diluted Shares Outstanding | 17.24% | -11.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||